NCT06272292 Biomechanical Investigation of Symptomatic FAI and Two Groups of Asymptomatic Controls
| NCT ID | NCT06272292 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Femoroacetabular Impingement |
| Study Type | INTERVENTIONAL |
| Enrollment | 99 participants |
| Start Date | 2022-07-28 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 99 participants in total. It began in 2022-07-28 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Femoroacetabular impingement (FAI) is an orthopaedic condition that is primarily characterized by the presence of anatomic bony abnormalities in the femoral head and/or the acetabulum resulting in an abnormal contact between the two during hip motion, especially in positions of increased hip flexion and rotation, ultimately leading to hip pain. Unfortunately, a FAI diagnosis is frequently only made once symptoms have become severe to an extent that they limit everyday life activities. Moreover, another important aspect that has been consistently overlooked in past FAI movement studies is the influence muscle strength and activation can have on movement pattern and symptom presentation. The diagnosis and management of FAI needs to be addressed through a more wholesome investigation of the biomechanical influence on the manifestation of symptoms. This project aims to further unravel the link between spinopelvic anatomy, its biomechanical contribution to femoro-pelvic motion and the manifestation of femoroacetabular impingement in adult male population. By, for the first time, integrating three-dimensional (3D) instrumented motion analysis with state-of-the-art full-body biplanar X-ray imaging (EOS imaging, Paris France), we will more specifically investigate the presence of an association between spinopelvic kinematics and the link to symptomatic FAI morphology, as well as investigate the presence of differences in these measures between symptomatic and asymptomatic subjects with comparable femoral morphology.
Eligibility Criteria
Exclusion Criteria: \- Participants in all three study groups will be excluded if x-ray scans shows a pincer FAI morphology or radiological sign of osteoarthritis. Inclusion Criteria: * All participants will be males aged between 21 and 35 years old. * For symptomatic CAM-FAI patients 1. The presence of CAM-FAI morphology at the head-neck junction of the femur 2. Alpha angle \>60 3. Reduced hip internal rotation (IR\<15) * For asymptomatic CAM controls: 1\. Exhibit asymptomatic CAM on x-ray scansAlpha angle \>60 * For Healthy control group: 1. Exhibit no symptoms or abnormal morphologies of the proximal femur (Alpha angle \>60 , IR\>15).
Contact & Investigator
Stijn Ghijselings, MD
PRINCIPAL INVESTIGATOR
Universitaire Ziekenhuizen KU Leuven
Frequently Asked Questions
Who can join the NCT06272292 clinical trial?
This trial is open to male participants only, aged 21 Years or older, up to 35 Years, studying Femoroacetabular Impingement. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06272292 currently recruiting?
Yes, NCT06272292 is actively recruiting participants. Contact the research team at stijn.ghijselings@uzleuven.be for enrollment information.
Where is the NCT06272292 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT06272292 clinical trial?
NCT06272292 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Stijn Ghijselings, MD at Universitaire Ziekenhuizen KU Leuven. The trial plans to enroll 99 participants.